secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vera Therapeutics, Inc. (VERA)
CIK:        0001831828
Form:       8-K
Filed at:   2023-03-28T23:59:59+00:00
Accession:  0000950170-23-010114
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vera Therapeutics reports FY2022 net loss $89.1M; positive atacicept interim data; plans Phase 3 in Q2 2023
--------------------------------------------------------------------------------

- Positive interim Phase 2b ORIGIN data: 41% mean proteinuria reduction vs baseline at 24 weeks in 150mg dose.
- 36-week data on track for Q2 2023; Phase 3 initiation planned for Q2 2023.
- FY2022 net loss $89.1M ($3.35/share) vs $32.6M ($2.43) prior year.
- Cash $114.7M as of Dec 31, 2022; raised ~$107.6M net in Feb 2023 offering.
- Prioritizing atacicept for IgAN; funds expected to last to early 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831828/000095017023010114/0000950170-23-010114-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831828/000095017023010114/vera-20230328.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-010114

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer